The Getinge’s Advanta V12 covered stent system. Credit: Getinge AB/Cision.

Getinge has received the European Union (EU) Medical Device Regulation (MDR) certificate for its Advanta V12 covered stent system.

This certification affirms the system’s compliance with EU standards for medical devices.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

It also extends the stent’s indications for use, specifically for patients with aortoiliac occlusive disease (AIOD).

The Advanta V12 covered stent system is designed for the treatment of patients diagnosed with renal artery stenosis and/or aortoiliac occlusive disease, including lesions at the aortic bifurcation, when endovascular therapy is needed.

It has precision, versatility and predictability and has been serving the medical community for over two decades. It is said to be the only durable solution in its category, supported by extensive clinical and real-world evidence.

See Also:

Getinge Vascular Systems vice-president Chad Carlton said: “Receiving the new EU MDR certification is a proud moment for Getinge. It is a clear reflection of our strategic vision, accompanied by the hard work and persistence of our team.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This investment in regulatory excellence not only supports our growth ambitions and future endeavours but also reinforces our commitment to making a positive impact on the lives of the patients we serve.”

The fully encapsulated Advanta V12 stent has been designed to restore and improve the patency of the iliac and renal arteries.

Last month, Getinge secured the US Food and Drug Administration’s 510(k) clearance for its Vasoview Hemopro 3 endoscopic vessel harvesting solution for cardiovascular surgery.

The solution is designed to improve procedural efficiency and patient outcomes, with features such as enhanced smoke evacuation, regulated energy control, an ergonomic game controller-style handle, and an integrated cable.